Journal of Korean Medicine for Obesity Research (한방비만학회지)

The Society of Korean Medicine for obesity Research (한방비만학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Combination Therapy with Anti-Obesity Herbal Medicine Including Ephedra Herba and Lorcaserin in Obese Patients: Two Case Reports

마황이 포함된 한방비만 처방과 Lorcaserin 병용 투여 후 호전된 비만 환자 치험 2예

  • Kim, Min-Jee (Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Dongguk University) ;
  • Choi, Han Seok (Department of Endocrinology Medicine, College of Medicine, Dongguk University) ;
  • Kim, Hojun (Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Dongguk University)
  • 김민지 (동국대학교 한의과대학 한방재활의학교실) ;
  • 최한석 (동국대학교 의과대학 내분비내과학교실) ;
  • 김호준 (동국대학교 한의과대학 한방재활의학교실)
  • Received : 2019.05.19
  • Accepted : 2019.06.03
  • Published : 2019.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Although there has been many studies about the co-administration of herb formula and western medicine, there is none about obesity. The aim of this study was to report the effects of co-administration of herb formula containing ephedra sinica and lorcaserin on two obese patients for about 2~4 months. During the treatment, we checked body weight and body composition, and collected blood samples to evaluate liver, kidney, thyroid function and lipid profile. This treatment not only decreased body weight but also improved body composition and lipid profile in both patients. There was no hepatic or renal toxicity, nor any serious side effects of treatment. This study demonstrated that co-administration of herb formula containing ephedra sinica and lorcaserin is a safe and effective therapy to lose weight and improve metabolic parameters for obese patients. Further large-scale clinical trials are needed to evaluate the anti-obesity effect of the combination of herbal and western medicines.

일차성 비만 환자 2명에게 마황이 포함된 한방비만 처방과 lorcaserin을 2~3개월 동안 병용 투여한 결과, 체중, 체지방량, 내장지방 단면적의 감소뿐 아니라 당대사와 지질대사의 개선을 확인할 수 있었다. 따라서 향후 효과적인 비만 치료법의 하나로 한양방 병용 투여를 사용할 수 있을 것이다.

Keywords

References

  1. KNHANES. Health behaviors and chronic disease statistics, 2016 [Internet]. Cheongju: Korea Centers for Disease Control and Prevention (KCDC); 2016 [cited 2019 May 18]. Available from: https://knhanes.cdc.go.kr/knhanes/sub04/sub04_03.do?classType=7.
  2. Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019 ; 15(5) : 288-98. https://doi.org/10.1038/s41574-019-0176-8
  3. Smith SR, Garvey WT, Greenway FL, Zhou S, Fain R, Pilson R, et al. Coadministration of Lorcaserin and Phentermine for weight management: A 12-week, randomized, pilot safety study. Obesity (Silver Spring). 2017 ; 25(5) : 857-65. https://doi.org/10.1002/oby.21811
  4. Jo GW, Ok JM, Kim SY, Lim YW. Review on the efficacy and safety of Mahuang and ephedrine in the treatment of obesity -Focused on RCT-. Korean J Med. 2017 ; 38(3) : 170-84. https://doi.org/10.13048/jkm.17034
  5. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. 2007 ; 132(6) : 2087-102. https://doi.org/10.1053/j.gastro.2007.03.052
  6. Seo MH, Lee WY, Kim SS, Kang JH, Kang JH, Kim KK, et al. 2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea. J Obes Metab Syndr. 2019 ; 28(1) : 40-5. https://doi.org/10.7570/jomes.2019.28.1.40
  7. Kim MK, Kim CS. Recent advances in anti-obesity agents. Korean J Med. 2018 ; 93(6) : 501-8. https://doi.org/10.3904/kjm.2018.93.6.501
  8. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000 ; 9(2) : 160-7. https://doi.org/10.1001/archfami.9.2.160
  9. Caixas A, Albert L, Capel I, Rigla M. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther. 2014 ; 8 : 1419-27.
  10. Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017 ; 3(1) : 3-14. https://doi.org/10.1002/osp4.84
  11. Brashier DB, Sharma AK, Dahiya N, Singh SK, Khadka A. Lorcaserin: A novel antiobesity drug. J Pharmacol Pharmacother. 2014 ; 5(2) : 175-8. https://doi.org/10.4103/0976-500X.130158
  12. Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol. 2018 ; 6(3) : 237-48. https://doi.org/10.1016/S2213-8587(17)30236-X
  13. Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord. 2001 ; 25(7) : 1095-9. https://doi.org/10.1038/sj.ijo.0801645
  14. Magkos F, Kavouras SA. Caffeine and ephedrine: physiological, metabolic and performance-enhancing effects. Sports Med. 2004 ; 34(13) : 871-89. https://doi.org/10.2165/00007256-200434130-00002
  15. White LM, Gardner SF, Gurley BJ, Marx MA, Wang PL, Estes M. Pharmacokinetics and cardioVAScular effects of ma-huang (Ephedra sinica) in normotensive adults. J Clin Pharmacol. 1997 ; 37(2) : 116-22. https://doi.org/10.1002/j.1552-4604.1997.tb04769.x
  16. Shannon JR, Gottesdiener K, Jordan J, Chen K, Flattery S, Larson PJ, et al. Acute effect of ephedrine on 24-h energy balance. Clin Sci (Lond). 1999 ; 96(5) : 483-91. https://doi.org/10.1042/cs0960483
  17. Song YK, Lim HH. Clinical application of Ma Huang in the obesity treatment. J Korean Med Obes Res. 2007 ; 7(1) : 1-7.
  18. Kim HJ, Han CH, Lee EJ, Song YK, Shin BC, Kim YK. A clinical practice guideline for Ma-huang (Ephedra sinica) prescription in obesity. J Korean Med Obes Res. 2007 ; 7(2) : 27-37.

Cited by

  1. 최근 10년간 한방비만학회지의 연구동향 분석: 2010-2019년 한방비만학회지 게재논문을 중심으로 vol.20, pp.2, 2019, https://doi.org/10.15429/jkomor.2020.20.2.149